4SC: RESMAIN study data to be presented at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting

4SC: RESMAIN study data to be presented at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting

Planegg-Martinsried, Germany, 15 September 2023 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), today announced that renowned dermato-oncology key opinion leader and study investigator, Professor Rudolf Stadler, University Hospital Johannes Wesling, Minden, Germany, will give an oral presentation on the findings from its RESMAIN study investigating the efficacy of resminostat as a maintenance treatment for cutaneous T-cell lymphoma, at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting at the Leiden University Medical Center, the Netherlands, September 21-23.  

Title: RESMAIN: Results of a multicenter, randomized, double blind, placebo controlled trial to evaluate resminostat for maintenance treatment in advanced stage Mycosis fungoides or Sézary syndrome 

Presenting Author: Professor Rudolf Stadler, University Hospital Johannes Wesling, Ruhr University Bochum, Minden, Germany 

Date and Time: Saturday 23^rd September, 9:10am CET 

Location: Leiden University Medical Center, the Netherlands, Room: O-143  

4SC will host a webinar to present an analysis of the findings showcased at the EORTC CLTG Annual Meeting on Wednesday 4^th October. Clinical experts, Professor Rudolf Stadler and Professor Julia Scarisbrick, will discuss the results and there will be the opportunity to ask questions during a Q&A session moderated by 4SC’s Chief Executive Officer, Jason Loveridge.  

Title: Presentation by Professor Rudolf Stadler and Professor Julia Scarisbrick on recent new positive data from the RESMAIN study 

Date and Time: Wednesday 4^th October, 3.00pm CET 

Register and submit questions: https://stream.brrmedia.co.uk/broadcast/64f5f2dac6e9d7476c27f154 

Jason Loveridge, Ph.D., Chief Executive Officer of 4SC, commented: “Our pivotal RESMAIN study was conducted at more than 50 clinical centers across Europe and by Yakult Honsha in Japan, investigating the efficacy of resminostat as a maintenance treatment for cutaneous T-cell lymphoma. Resminostat is an orally administered class I, IIb and IV histone deacetylase (HDAC) inhibitor which is well tolerated and can inhibit tumor growth and proliferation, cause tumor regression, and strengthen the body’s immune response to cancer. We look forward to presenting the results of the trial for the first time during this prestigious conference and our live webinar in October.”